Alua Imantay

Ms. Alua Imantay


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2025 in Nanomaterials
Verified
Journal Article
Open access
PDF file
AIAlua Imantay
Alua Imantay
NMNariman Mashurov
Nariman Mashurov
BZBalnur A. Zhaisanbayeva
Balnur A. Zhaisanbayeva
EMEllina Mun
Ellina Mun
Doxorubicin (DOX) is one of the most widely used chemotherapy drugs in the treatment of both solid and liquid tumors in patients of all age groups. However, it is likely to produce several side effects that include doxorubicin cardiomyopathy. Nanoparticles (NPs) can offer targeted delivery and release of the drug, potentially increasing treatment efficiency and alleviating side effects. This makes them a viable vector for novel drug delivery systems. Currently, DOX is commonly conjugated to NPs by non-covalent conjugation–physical entrapping of the drug using electrostatic interactions, van der Waals forces, or hydrogen bonding. The reported downside of these methods is that they provide a low drug loading capacity and a higher drug leakage possibility. In comparison to this, the covalent conjugation of DOX via amide (typically formed by coupling carboxyl groups on DOX with amine groups on the nanoparticle or a linker, often facilitated by carbodiimide reagents), hydrazone (which results from the reaction between hydrazines and carbonyl groups, offering pH-sensitive cleavage for controlled release), or disulfide bonds (formed through the oxidation of thiol groups and cleavable by intracellular reducing agents such as glutathione) is more promising as it offers greater bonding strength. This review covers the covalent conjugation of DOX to three different types of NPs—metallic, silica/organosilica, and polymeric—including their corresponding release rates and mechanisms.

5 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EMEllina Mun
Ellina Mun
BZBalnur A. Zhaisanbayeva
Balnur A. Zhaisanbayeva
AIAlua Imantay
Alua Imantay
NMNariman Mashurov
Nariman Mashurov
Doxorubicin (DOX) is one of the most widely used chemotherapy drugs in the treatment of both solid and liquid tumours in patients of all age groups. However, it is likely to produce several side effects that include doxorubicin cardiomyopathy. Nanoparticles (NPs) can offer targeted delivery and release of the drug, potentially increasing the treatment efficiency and alleviating the side effects. This makes them a viable vector for novel drug delivery systems. Currently, DOX is commonly conjugated to NPs by non-covalent conjugation – physical entrapping of the drug using electrostatic interactions, van der Waals forces, or hydrogen bonding. The reported downside of these methods is that they provide low drug loading capacity and higher drug leakage possibility. In comparison to this, covalent conjugation of DOX via amide, hydrazone, or disulfide bonds is more promising, as it offers greater bonding strength. This review covers the covalent conjugation of DOX to three different types of NPs – metallic, silica/organosilica, and polymeric, including their corresponding release rates and mechanisms.